GlassScriptPhysician profile
Marisa A Braun
NPI 1851312631
$3,923.30
in general payments reported to CMS, 2019-2025
31 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $286 · 2021: $664 · 2022: $326 · 2023: $680 · 2024: $405 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.72 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $534.61 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $271.35 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $252.43 | 2023-2024 | Sotyktu |
| Celgene Corporation | $243.63 | 2019 | |
| Amgen INC. | $206.57 | 2019-2025 | Otezla |
| Pfizer INC. | $178.36 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $165.74 | 2019-2025 | |
| Lilly USA, LLC | $164.89 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Revance Therapeutics, INC. | $134.85 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $122.85 | 2021-2024 | Dupixent |
| Leo Pharma INC. | $108.36 | 2019-2021 | |
| Galderma Laboratories, L.P. | $97.51 | 2019-2024 | |
| Merz North America, INC. | $96.73 | 2019-2023 | Xeomin |
| Allergan, INC. | $91.57 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $75.61 | 2022-2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.43 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $59.99 | 2022-2025 | Opzelura |
| Genzyme Corporation | $48.48 | 2019 | |
| Almirall LLC | $48.47 | 2020-2021 | |
| Sientra, INC. | $47.57 | 2019 | |
| Strata Skin Sciences, INC. | $30.78 | 2019 | |
| Aclaris Therapeutics, INC. | $22.73 | 2019 | |
| Genentech USA, INC. | $20.25 | 2019 | |
| Biofrontera INC. | $20.00 | 2019 | |
| Organon LLC | $19.97 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.48 | 2019 | |
| Vyne Pharmaceuticals INC. | $16.72 | 2020 | |
| Dermira, INC. | $16.27 | 2020 | |
| Epi Health, LLC | $14.38 | 2022 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.